Essay Contest Spotlights Malaria in Kenya

Students in Siaya, Western Kenya, reflect on the various ways the disease has affected their families.

View the slide show »

Student Essay Contest


Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »


News and announcements

GSK announces EU regulatory submission for RTS,S malaria vaccine candidate

The regulatory application to the European Medicines Agency (EMA) will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state for a disease recognized by the World Health Organization as of major public health interest, but intended exclusively for use outside the EU.


PLOS Medicine publishes additional findings and data on RTS,S/AS01

Article reports findings on safety and efficacy of the malaria vaccine candidate over an 18-month period following vaccination at 11 African sites across a wide range of malaria transmission settings.


MVI Names New Director of Research & Development

Dr. Rick King is an accomplished scientist with more than 25 years of experience in the public and private sectors, in both for-profit and nonprofit organizations.

Joint statement from MVI, International AIDS Vaccine Initiative, Aeras

It’s time for AIDS, TB and malaria to go the way of smallpox and polio.


Events and Conferences

ASTMH 63nd Annual Meeting
November 2–6, 2014